tradingkey.logo

BRIEF-CARsgen Announces Topline Results From China GC/GEJ Pivotal Phase II Clinical Trial of Claudin18.2 CAR-T

ReutersDec 30, 2024 3:21 PM

- CARsgen Therapeutics Holdings Ltd 2171.HK:

  • CARSGEN ANNOUNCES POSITIVE TOPLINE RESULTS FROM CHINA GC/GEJ PIVOTAL PHASE II CLINICAL TRIAL OF CLAUDIN18.2 CAR-T (SATRI-CEL)

  • CARSGEN THERAPEUTICS HOLDINGS LTD - STUDY MEETS PRIMARY ENDPOINT OF IMPROVED PFS

  • CARSGEN THERAPEUTICS HOLDINGS LTD: ANTICIPATE SUBMITTING AN NDA TO NMPA IN FIRST HALF OF 2025

Source text: ID:nPn8yM75Ja

Further company coverage: 2171.HK

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI